Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,129.08 -10.18 -0.32%
FTSE 100 6,587.20 3.03 0.05%
DAX 9,304.76 -13.06 -0.14%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Covidien and VIDA Diagnostics Collaborate to Expand Minimally Invasive Treatment of Lung Disease



  Covidien and VIDA Diagnostics Collaborate to Expand Minimally Invasive
  Treatment of Lung Disease

Combined use of market-leading diagnostic technologies opens door to treatment
                                   options

Business Wire

MINNEAPOLIS -- April 11, 2013

Covidien (NYSE: COV), a leading global provider of healthcare products, today
announced an agreement with VIDA Diagnostics, a pioneer in quantitative
pulmonary imaging analysis software. Under the agreement, Covidien will
distribute VIDA’s Apollo® pulmonary imaging software services.

“We are committed to improving patient outcomes. The combination of our
technologies results in a powerful, minimally invasive, more informative
imaging solution for areas of the lung not accessible by traditional
bronchoscopy and for patients who cannot tolerate more invasive procedures,”
said Michael Minette, Vice President, Interventional Lung Solutions, Covidien.
“This collaboration brings together two companies dedicated to the early
detection, evaluation and treatment of pulmonary disease.”

This agreement enables Covidien to offer a unique combination of
market-leading technologies from VIDA and Covidien’s i-Logic™ lung navigation
system. i-Logic provides pulmonary physicians and other clinicians with
enhanced detail for the minimally invasive diagnosis and treatment planning of
lung cancer, chronic obstructive pulmonary disease (COPD), asthma and other
lung diseases.

Lung cancer is a public health issue that affects more than 370,000 Americans
and represents a $14 billion expense each year, according to the American Lung
Association. COPD, also known as emphysema and chronic bronchitis, is the
third leading cause of death in the United States and adds $18 billion in
annual healthcare spend. Asthma has an annual direct healthcare spend of $56
billion a year in the United States.

The i-Logic system uses advanced Electromagnetic Navigation Bronchoscopy®
technology to extend beyond the capabilities of the bronchoscope to distant
regions of the lungs not accessible through traditional bronchoscopy. The
i-Logic system enables physicians to locate previously inaccessible small lung
lesions for diagnostic testing and enhancing treatment options. The Apollo
platform provides more precise analyses of imaging data for more objective
insights on patient diagnoses and treatment options.

“The integration of quantitative pulmonary image analysis with innovative
devices and therapies is an emerging requirement to obtain effective outcomes
in patients with lung disease,” said Scott Ferguson, M.D., Associate Professor
and Director of Interventional Pulmonology in the Division of Allergy,
Pulmonary and Critical Care Medicine, University of Wisconsin School of
Medicine and Public Health; who has worked as a consultant to Covidien.
“Together, VIDA and Covidien, leaders in their specialized fields, provide a
more unified, comprehensive approach to managing patients with lung disease.”

“Our partnership with Covidien is an opportunity to transform the management
of patients with lung disease to an objective, evidence-based approach leading
to more precise diagnoses and targeted therapies,” said Susan A. Wood, Ph.D.,
President and CEO of VIDA Diagnostics. “We are thrilled to be collaborating
with the leaders in minimally invasive techniques to bring new diagnostic and
therapeutic planning opportunities for patients with lung disease.”

About Covidien

Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers value
through clinical leadership and excellence. Covidien manufactures, distributes
and services a diverse range of industry-leading product lines in three
segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012
revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70
countries, and its products are sold in over 140 countries. Please visit
www.covidien.com to learn more about our business.

Contact:

Covidien
John Jordan, 508-452-4891
Manager, Communications
Surgical Solutions
john.jordan@covidien.com
or
Marguerite Copel, 203-821-4720
Vice President, Communications
Surgical Solutions
marguerite.copel@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
todd.carpenter@covidien.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement